Global Vaccines Market

 

 

The Global Vaccines as a Service market was valued at USD 41.4 billion in 2020 which expected to reach USD 67.2 billion by 2027 at a CAGR 10.2% from 2020-2027.

 

A vaccine is a substance that is introduced into the body to prevent infection or to control disease due to a certain pathogen, which is a disease-causing organism, such as a virus, bacteria, or parasite. By inducing an immune response, the vaccine teaches the body how to defend itself against the pathogen. Preventive vaccines work by introducing a small component or a non-harmful form of the pathogen (called the foreign antigen) into the body to protect an individual from infection or disease. The body generates antibodies (via the humoral response), killer cells (via the cell mediated response), or both in response to the pathogen.

 

 

Drivers: The global vaccines market is expected to grow due to the high prevalence of diseases that require vaccine administration and the growing use of vaccines for various infectious diseases such as influenza, pneumonia, and rotavirus infection. Furthermore, governments' emphasis on immunisation programmes helps to raise public awareness about vaccine safety and availability. Furthermore, various technologies used in the development of effective vaccines contribute to the growth of the vaccine market.

 

 

Restraints: These lengthy vaccine development timelines stifle the development of new vaccines, limiting market growth. The decline is primarily due to drug supply and demand failures caused by the COVID-19 outbreak around the world. Market growth is being hampered by biologic drug shortages caused by insufficient biologics production.

 

 

Impact of Covid-19

 

The majority of markets, including the vaccine market, are declining as a result of the outbreak. The pandemic has had a negative impact on the global vaccine market, as most countries have implemented lockdown measures to combat the outbreak. Additionally, the contributions of the companies are collaborating to accelerate the development, manufacture, and delivery of COVID-19 vaccines, diagnostics, and treatments.

 

 

Segmentation By Type: Global Vaccine Market is classified on the basis of Type into Live Attenuated Vaccines, Inactivated Vaccines, Subunit and Conjugate vaccines, Toxoid Vaccines, and Combination Vaccines.

 

 

Segmentation By Route of Administration: Global Vaccine Market is classified on the basis of Route of Administration into Intramuscular, Subcutaneous, Oral, and Other Routes of Administration.

 

 

Segmentation By Valence: Global Vaccine Market is classified on the basis of Valence into Monovalent and Polyvalent (Multivalent).

 

 

Segmentation By COVID-19 Vaccines Market: Global Vaccine Market is classified on the basis of COVID-19 Vaccines into Prevalence, COVID-19 Vaccines Market Size and Forecast, Initiatives for Coronavirus Vaccine Development, Authorized Vaccines & Phase 3 Vaccine Candidates, COVID-19 Vaccine Pipeline Analysis, Purchase Data for Covid-19 Vaccines, and Vaccination Coverage.

 

 

Segmentation By Region: Global Vaccine Market is classified on the basis of Region into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

 

 

Competitive Landscape: The key players of Global Vaccine Market are Sanofi (France), Merck & Co., Inc. (U.S.), GlaxoSmithKline plc (U.K.), Pfizer Inc. (U.S.), Johnson & Johnson (U.S.), Daiichi Sankyo Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan), CSL Limited (Australia), Emergent BioSolutions Inc. (U.S.), and AstraZeneca PLC (U.K.).

 

 

Industrial Development

 

  • In October 2021, the US Food and Drug Administration (FDA) granted Pfizer an Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine for children aged 5 to 11.
  • In August 2021, the Pfizer-BioNTech COVID-19 vaccine COMIRNATY was given full US FDA approval for people aged 16 and up.
  • Shingrix (Zoster Vaccine Recombinant, Adjuvanted) was approved by the US Food and Drug Administration in July 2021 for the prevention of shingles (herpes zoster) in adults aged 18 and older who are or will be at increased risk of shingles due to immunodeficiency or immunosuppression caused by a known disease or therapy.

 

Market Taxonomy

 

By Type

 

  • Live Attenuated Vaccines
  • Inactivated Vaccines
  • Subunit and Conjugate vaccines
  • Toxoid Vaccines
  • Combination Vaccines

 

By Route of Administration

 

  • Intramuscular
  • Subcutaneous
  • Oral
  • Other Routes of Administration

 

By Valence

 

  • Monovalent
  • Polyvalent (Multivalent)

 

By COVID-19 Vaccines Market                

            

  • Prevalence
  • COVID-19 Vaccines Market Size and Forecast
  • Initiatives for Coronavirus Vaccine Development
  • Authorized Vaccines & Phase 3 Vaccine Candidates
  • COVID-19 Vaccine Pipeline Analysis
  • Purchase Data for Covid-19 Vaccines
  • Vaccination Coverage

 

By Region

 

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

 

Key Questions Addressed by the Report

 

  • What are the Key Opportunities in Global Vaccines Market?
  • What will be the growth rate from 2020 to 2027?
  • Which segment/region will have highest growth?
  • What are the factors that will impact/drive the Market?
  • What is the competitive Landscape in the Industry?
  • What is the role of key players in the value chain?

Global Vaccine Market TOC

 

 

1 Introduction       


1.1 Objective of the Study
1.2 Market definition
1.3 Market Scope

 

 

2 Research Methodology

 

2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources

 

 

3 Executive Summary


4 Global Vaccine Market Outlook


4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

 

 

5. Global Vaccine Market, By Type


5.1 Y-o-Y Growth Comparison, By Type
5.2 Vaccine Market Share Analysis, By Type
5.3 Vaccine Market Size and Forecast, By Type
5.3.1 Live Attenuated Vaccine

5.3.2 Inactivated Vaccine

5.3.3 Subunit and Conjugate Vaccine

5.3.4 Toxoid Vaccine

5.3.5 Combination Vaccine

 

 

6. Global Vaccine Market, By Route of Administration

 

6.1 Y-o-Y Growth Comparison, By Route of Administration

6.2 Vaccine Market Share Analysis, By Route of Administration

6.3 Vaccine Market Size and Forecast, By Route of Administration

6.3.1 Intramuscular

6.3.2 Subcutaneous

6.3.3 Oral

6.3.4 Other Routes of Administration

 

 

7. Global Vaccine Market, By Valence

 

7.1 Y-o-Y Growth Comparison, By Valence

7.2 Vaccine Market Share Analysis, By Valence

7.3 Vaccine Market Size and Forecast, By Valence

7.3.1 Monovalent

7.3.2 Polyvalent (Multivalent)

 

 

8. Global Vaccine Market, By COVID-19 Vaccines Market

 

8.1 Y-o-Y Growth Comparison, By COVID-19 Vaccines Market

8. Vaccine Market Share Analysis, By COVID-19 Vaccines Market

8.3 Vaccine Market Size and Forecast, By COVID-19 Vaccines Market

8.3.1 Prevalence

8.3.2 COVID-19 Vaccines Market Size and Forecast

8.3.3 Initiatives for Coronavirus Vaccine Development

8.3.4 Authorized Vaccines & Phase 3 Vaccine Candidates

8.3.5 COVID-19 Vaccine Pipeline Analysis

8.3.6 Purchase Data for Covid-19 Vaccines

 

 

9. Global Vaccine Market, By Region

 

9.1 Vaccine Market Share Analysis, By Region

9.2 Vaccine Market Size and Forecast, By Region

9.3 Vaccine Market Size and Forecast, By Region

 

 

10. North America Vaccine Analysis and Forecast (2021-2027)

 

10.1 Introduction

10.2 North America Vaccine Market Share Analysis, By Software Type

10.3 North America Vaccine Market Size and Forecast, By Route of Administration

10.4 North America Vaccine Market Size and Forecast, By Valence

10.5 North America Vaccine Market Size and Forecast, By COVID-19 Vaccines Market

10.6 North America Vaccine Market Size and Forecast, By Country

10.6.1 US

10.6.2 Canada

 

 

11. Europe Vaccine Market Analysis and Forecast (2021-2027)

 

11.1 Introduction

11.2 Europe Vaccine Market Share Analysis, By Software Type

11.3 Europe Vaccine Market Size and Forecast, By Route of Administration

11.4 Europe Vaccine Market Size and Forecast, By Valence

11.5 Europe Vaccine Market Size and Forecast, By COVID-19 Vaccines Market

11.6 Europe Vaccine Market Size and Forecast, By Country

11.6.1 UK

11.6.2 Germany

11.6.3 France

11.6.4 Italy

11.6.5 Spain

11.6.6 Netherland

 

 

12. Asia Pacific Vaccine Market Analysis and Forecast (2021-2027)

 

12.1 Introduction

12.2 Asia Pacific Vaccine Market Share Analysis, By Software Type

12.3 Asia Pacific Vaccine Market Size and Forecast, By Route of Administration

12.4 Asia Pacific Vaccine Market Size and Forecast, By Valence

12.5 Asia Pacific Vaccine Market Size and Forecast, By COVID-19 Vaccines Market  

12.6 Asia Pacific Vaccine Market Size and Forecast, By Country

12.6.1 China

12.6.2 Japan

12.6.3 India

12.6.4 Australia

 

 

13. Latin America Vaccine Market Analysis and Forecast (2021-2027)

 

13.1 Introduction

13.2 Latin America Vaccine Market Share Analysis, By Software Type

13.3 Latin America Vaccine Market Size and Forecast, By Route of Administration

13.4 Latin America Vaccine Market Size and Forecast, By Valence

13.5 Latin America Vaccine Market Size and Forecast, By COVID-19 Vaccines Market

13.6 Latin America Vaccine Market Size and Forecast, By Country

13.6.1 Brazil

13.6.2 Rest of Latin America

 

 

14 Middle East Vaccine Market Analysis and Forecast (2021-2027)


14.1 Introduction

14.2 Middle East Vaccine Market Share Analysis, By Software Type

14.3 Middle East Vaccine Market Size and Forecast, By Route of Administration

14.4 Middle East Vaccine Market Size and Forecast, By Valence

14.5 Middle East Vaccine Market Size and Forecast, By COVID-19 Vaccines Market

14.6 Middle East Vaccine Market Size and Forecast, By Country

14.6.1 Saudi Arabia

14.6.2 UAE

14.6.3. Egypt

14.6.4. Kuwait

14.6.5. South Africa

 

 

15 Competitive Analysis

 

15.1 Competition Dashboard

15.2 Market share Analysis of Top Vendors

15.3 Key Development Strategies

 

 

16. Company Profiles

 

16.1 Sanofi (France)

 

16.1.1 Overview

16.1.2 Offerings

16.1.3 Key Financials

16.1.4 Business Segment & Geographic Overview

16.1.5 Key Market Developments

16.1.6 Key Strategies

 

 

16.2 Merck & Co., Inc. (U.S.)

 

16.2.1 Overview

16.2.2 Offerings

16.2.3 Key Financials

16.2.4 Business Segment & Geographic Overview

16.2.5 Key Market Developments

16.2.6 Key Strategies

 

 

16.3 GlaxoSmithKline plc (U.K.)

 

16.3.1 Overview

16.3.2 Offerings

16.3.3 Key Financials

16.3.4 Business Segment & Geographic Overview

16.3.5 Key Market Developments

16.3.6 Key Strategies

 

 

16.4 AstraZeneca PLC (U.K.)

 

16.4.1 Overview

16.4.2 Offerings

16.4.3 Key Financials

16.4.4 Business Segment & Geographic Overview

16.4.5 Key Market Developments

16.4.6 Key Strategies

 

 

16.5 CSL Limited (Australia)

 

16.5.1 Overview

16.5.2 Offerings

16.5.3 Key Financials

16.5.4 Business Segment & Geographic Overview

16.5.5 Key Market Developments

16.5.6 Key Strategies

 

 

16.6 Takeda Pharmaceutical Company Limited (Japan)

 

16.6.1 Overview

16.6.2 Offerings

16.6.3 Key Financials

16.6.4 Business Segment & Geographic Overview

16.6.5 Key Market Developments

16.6.6 Key Strategies

 

 

16.7 Johnson & Johnson (U.S.)

 

16.7.1 Overview

16.7.2 Offerings

16.7.3 Key Financials

16.7.4 Business Segment & Geographic Overview

16.7.5 Key Market Developments

16.7.6 Key Strategies